

Aridis Pharmaceuticals CEO Invited to Speak on Infectious Disease Panel at 2016 Anti-Infectives Rx Conference

SAN JOSE, Calif., September 21, 2016 - Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that CEO Vu Truong, Ph.D., will participate on a panel at the 2016 Anti-Infectives Rx Conference, held September 21, 2016, and hosted by Boston Biotech Conferences.

Event Details

Panel: Breakthroughs in Infectious Disease Programs

Date: September 21, 2016

Time: 4:10 p.m. – 4:40 p.m. (Eastern Time)

Location: Harvard Medical School-Joseph B. Martin Conference Center, Boston

Dr. Truong will be joined by fellow panelists Chip Clark, CEO and President of Genocea; David Huang, CMO of MotifBio; Larry Kauvar, Chief Scientist of Trellis Bioscience; and Ankit Mahadevia, CEO of Spero Therapeutics. The panel will be moderated by Jeffrey Moore, President of MP Healthcare.

About Aridis Pharmaceuticals, Inc.

Aridis is a privately held biopharmaceutical company applying its proprietary monoclonal antibody discovery technology MabIgX™ to produce novel infectious disease focused therapies. Aridis' product pipeline includes AR-101 (Aerumab™) anti-*Pseudomonas aeruginosa* LPS human monoclonal antibody; AR-301 (Salvecin™) anti-*Staphylococcus aureus* human monoclonal antibody to treat acute pneumonia; Aerucin™, a broadly reactive anti-*Pseudomonas aeruginosa* human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR-401 anti-*Acinetobacter baumannii* human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Contacts:

[Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D. (investors)

jdrumm@tiberend.com

(212) 375-2664

Andrew Mielach (media)

amielach@tiberend.com

(212) 375-2694